MedTrace Logo

Pimavanserin for Sleep in Parkinson Disease

NCT05796167 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-12-20

No results posted yet for this study

Summary

This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.

Conditions

  • Parkinson Disease

Interventions

DRUG

Pimavanserin

Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    collaborator INDUSTRY

  • State University of New York - Downstate Medical Center

    lead OTHER

Principal Investigators

  • Christian J Amlang, MD · State University of New York - Downstate Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2024-06-24
Completion
2024-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05796167 on ClinicalTrials.gov